MRD status stratifies morphologic response by Kaplan-Meier analysis. Patients achieving mCR showed a 55% 5-year DFS (A); 20% of these patients (113 of 576 patients) had detectable MRD with 38% 5-year DFS (B). Patients with >5% morphologic blasts (no mCR) had a 5-year DFS of 34% (A); however, in 36% of these patients (67 of 185 patients), the myeloid progenitor cells were phenotypically normal (C) with a 5-year DFS of 52%. Patients with >15% morphologic blasts (D) showed a similar pattern; 27% of patients (25 of 91 patients) were phenotypically normal with a 5-year DFS of 60% (E). (E) Patients with increased phenotypically abnormal blasts at EOI1 (66 of 91 patients) exhibited a dismal 5-year DFS of 17%.